Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

• Status: Terminated
• Trial end date: 2017-09-04
• Target enrollment: 0
• Participant gender: All

Summary

This pilot phase II trial studies how well vincristine sulfate liposome works in treating patients with acute myeloid leukemia that has returned after a period of improvement or has not responded to previous treatment. Drugs used in chemotherapy, such as vincristine sulfate liposome, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Liposomal encapsulation prolongs bioavailability (proportion of drug that enters the circulation when introduced into the body) of vincristine sulfate, and may increase its delivery to cancer cells with fewer side effects.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Collaborators: National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc
• Treatments: Vincristine

Criteria

Inclusion Criteria:

• Patients must have histologically or cytologically documented relapsed and/or refractory acute myeloid leukemia

• Patients must be ineligible for, refused or having failed at least one previous salvage regimen

• Eastern Cooperative Oncology Group (ECOG) performance status of =< 3

• Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation

• Fertile men must practice effective contraceptive methods during the study period, unless documentation of infertility exists

• Mentally competent, ability to understand and willingness to sign the informed consent form

• No serious medical illness that would potentially increase patients' risk for toxicity

• No active central nervous system (CNS) disease

• No active uncontrolled bleeding/bleeding diathesis

• No condition or abnormality which may, in the opinion of the investigator, compromise the safety of the patient

• No unwillingness or inability to follow protocol requirements

• No evidence of ongoing, uncontrolled infection

• No requirement for immediate palliative treatment of any kind including surgery

• No option for immediate bone marrow transplant unless patient refuses this therapy

• Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =< 3 x upper normal limit (UNL), alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =< 3 x UNL

• Bilirubin =< 3 x UNL

• Glomerular filtration rate (GFR) > 50 ml/min/1.72 m^2 or creatinine < 2 g/dL

Exclusion Criteria:

• Serious medical illness or severe debilitating pulmonary disease that would potentially increase the patients' risk for toxicity

• Patients with persistent grade 3 or higher prior vincristine (VCR) (vincristine sulfate)-related neuropathy

• Patients with active central nervous system (CNS) disease

• Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g., active peptic ulcer disease)

• Pregnant women, or women of child-bearing potential not using reliable means of contraception

• Lactating females

• Fertile men unwilling to practice contraceptive methods during the study period

• Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients

• Unwilling or unable to follow protocol requirements

• Evidence of ongoing, uncontrolled infection

• Patients with known human immunodeficiency virus (HIV) infection

• Requirement for immediate palliative treatment of any kind including surgery

• Evidence of inadequate hepatic function (aspartate aminotransferase [AST/SGOT] =< 3 x upper normal limit [UNL], alanine aminotransferase [ALT/SGPT] =< 3 x UNL [=< 5 x ULN if liver metastases present], bilirubin =< 1.5 x UNL)

• Evidence of inadequate renal function (creatinine > 2 g/dL)